Merck Long Term Debt 2010-2023 | MRK

Merck long term debt from 2010 to 2023. Long term debt can be defined as the sum of all long term debt fields.
  • Merck long term debt for the quarter ending December 31, 2023 was $33.683B, a 17.18% increase year-over-year.
  • Merck long term debt for 2023 was $33.683B, a 17.18% increase from 2022.
  • Merck long term debt for 2022 was $28.745B, a 6.34% decline from 2021.
  • Merck long term debt for 2021 was $30.69B, a 21.02% increase from 2020.
Merck Annual Long Term Debt
(Millions of US $)
2023 $33,683
2022 $28,745
2021 $30,690
2020 $25,360
2019 $22,736
2018 $19,806
2017 $21,353
2016 $24,274
2015 $23,829
2014 $18,699
2013 $20,539
2012 $16,254
2011 $15,525
2010 $15,482
2009 $16,095
Merck Quarterly Long Term Debt
(Millions of US $)
2023-12-31 $33,683
2023-09-30 $33,972
2023-06-30 $34,072
2023-03-31 $28,074
2022-12-31 $28,745
2022-09-30 $28,482
2022-06-30 $28,684
2022-03-31 $30,586
2021-12-31 $30,690
2021-09-30 $22,907
2021-06-30 $24,033
2021-03-31 $24,002
2020-12-31 $25,360
2020-09-30 $26,321
2020-06-30 $26,156
2020-03-31 $21,637
2019-12-31 $22,736
2019-09-30 $22,677
2019-06-30 $22,771
2019-03-31 $22,721
2018-12-31 $19,806
2018-09-30 $19,936
2018-06-30 $19,959
2018-03-31 $21,501
2017-12-31 $21,353
2017-09-30 $21,838
2017-06-30 $21,706
2017-03-31 $23,437
2016-12-31 $24,274
2016-09-30 $23,656
2016-06-30 $23,642
2016-03-31 $23,656
2015-12-31 $23,829
2015-09-30 $24,124
2015-06-30 $24,069
2015-03-31 $25,506
2014-12-31 $18,699
2014-09-30 $18,566
2014-06-30 $18,590
2014-03-31 $19,589
2013-12-31 $20,539
2013-09-30 $22,647
2013-06-30 $22,526
2013-03-31 $16,089
2012-12-31 $16,254
2012-09-30 $17,571
2012-06-30 $15,057
2012-03-31 $15,228
2011-12-31 $15,525
2011-09-30 $15,692
2011-06-30 $15,783
2011-03-31 $15,644
2010-12-31 $15,482
2010-09-30 $14,032
2010-06-30 $13,835
2010-03-31 $15,281
2009-12-31 $16,095
2009-09-30 $8,205
2009-06-30 $8,181
2009-03-31 $3,939
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $321.391B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $708.528B 117.99
Novo Nordisk (NVO) Denmark $577.276B 47.56
Johnson & Johnson (JNJ) United States $360.407B 14.30
AbbVie (ABBV) United States $300.196B 15.26
AstraZeneca (AZN) United Kingdom $219.666B 19.46
Novartis AG (NVS) Switzerland $198.840B 14.10
Pfizer (PFE) United States $149.038B 14.38
Sanofi (SNY) $120.637B 10.86
Innoviva (INVA) United States $0.959B 6.77